Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-13 | Maykin Ho, Ph.D. has more than 30 years of experience in the healthcare and finance industries. She serves on the boards of directors for Agios Pharmaceuticals, FibroGen, Inc., Grail Inc., Parexel, the Aaron Diamond AIDS Research Center, and the Institute for Protein Innovation. The Audit Committee is currently composed of four directors: Mr. Hombach (Chair), Dr. Heron, Dr. Ho and Dr. Lawlis. Ms. Anderson was a member of the Audit Committee when the Audit Committee submitted this report. Subsequently, Ms. Anderson joined the Compensation Committee and was replaced on the Audit Committee by Dr. Ho. The Science and Technology Committee is currently composed of six directors: Dr. Dere (Chair), Mr. Grey, Dr. Heron, Dr. Ho, Dr. Lawlis and Dr. Slamon. |
| 2022-04-12 | Maykin Ho, Ph.D., 69, Director Since February 2021, Director, Agios Pharmaceuticals; Director, FibroGen, Inc.; Director, Parexel; Director, the Aaron Diamond AIDS Research Center and Institute for Protein Innovation. Audit Committee Member. 2021 INDEPENDENT DIRECTOR COMPENSATION: Fees Earned or Paid in Cash $88,500, Stock Awards $397,312, Total $485,812. |
| 2023-04-11 | Maykin Ho, Ph.D. joined our board in February 2021. Dr. Ho serves on the boards of Agios Pharmaceuticals, a public pharmaceutical company, FibroGen, Inc., a public biopharmaceutical company, Neumora Therapeutics, Inc., a private biotechnology company, and Parexel, a private biopharmaceutical services company, the Aaron Diamond AIDS Research Center at Columbia University, and the Institute for Protein Innovation founded by Dr. Timothy Springer of Harvard University. Dr. Ho is also a venture partner of Qiming Venture Partners and a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong. Dr. Ho was previously a member of the board of directors of Grail, Inc., a private cancer detection company that was acquired by Illumina. Dr. Ho is also a retired partner of the Goldman Sachs Group where she served as senior biotechnology analyst, co-head of global healthcare investment research, and advisory director for healthcare investment banking. Prior to Goldman Sachs, Dr. Ho held various managerial positions in licensing, strategic planning, marketing and research at DuPont-Merck Pharmaceuticals and DuPont de Nemours & Company. Dr. Ho was a postdoctoral fellow at Harvard Medical School and a graduate of the Advanced Management Program at The Fuqua School of Business, Duke University. Dr. Ho received a Ph.D. in Microbiology and Immunology and a B.S. from the State University of New York, Downstate Medical Center. |
| 2024-04-09 | Maykin Ho, Ph.D. joined our Board in February 2021. ... 2023 Independent Director Compensation ... Maykin Ho, Ph.D. 88,500 Fees Earned or Paid in Cash, 385,438 Stock Awards, 473,938 Total. |
| 2025-04-08 | Maykin Ho, Ph.D. joined our Board in February 2021. Dr. Ho has been a venture partner of Qiming Venture Partners. Dr. Ho currently serves on the boards of Agios Pharmaceuticals Inc., FibroGen, Inc., and Neumora Therapeutics, Inc. 2024 Non-Employee Director Compensation: Maykin Ho, Ph.D. received total compensation of $467,045. |
| Filing Date | Source Excerpt |
|---|---|
| 2020-04-23 | Maykin Ho, Ph.D., age 67, joined our board of directors in December 2018. ... Dr. Ho became a member of the audit committee on June 5, 2019. |
| 2021-04-13 | Maykin Ho, Ph.D., age 68, joined our board of directors in December 2018. ... Our audit committee consists of Mr. Edwards, Dr. Ho and Mr. Lema. ... Dr. Ho was a member of our audit committee throughout 2020. ... The following table sets forth information regarding compensation earned by or paid to our non-employee directors during fiscal year 2020: ... Maykin Ho, Ph.D. Fees Earned or Paid in Cash: $60,000, Stock Option Awards: $148,442, RSU Awards: $153,643, Total: $362,085. |
| 2022-04-29 | Maykin Ho, Ph.D., age 69, joined the Board in 2018... She serves on Audit committee... Total compensation in 2021 was $247,072. |
| 2023-04-27 | Maykin Ho, Ph.D., age 70, joined the Board in December 2018. ... We believe Dr. Ho is qualified to serve on the Board because of her substantial experience in the healthcare and finance industries and her expertise in analysis of science and biotechnology. ... Our Audit Committee consists of Mr. Edwards, Dr. Ho and Mr. Lema. ... The following table sets forth information regarding compensation earned by or paid to our non-employee directors during fiscal year 2022: ... Maykin Ho, Ph.D. $344,454 ... |
| 2024-04-24 | Maykin Ho, Ph.D., age 71, joined our board of directors in December 2018. Dr. Ho serves on the Audit Committee. Director compensation table shows total $375,534. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22